6Kotloff KL,Winickoff TP,Ivanoff B,et al.Global burden of Shigella infections:implications for vaccine development implementation of control strategies[J].Bull WHO,1999,77(8):651.
7Jamal W,Rotimi VO,Pal T,et al.Comparative in vitro activity of tigecycline and other antimicrobial agents against Shigella species from Kuwait and the United Arab of Emirates[J].Infect Public Health,2010,3(1):35.
8Mamishi S,Mashoori N,Mahboobi N,et al.Increasing resistance to nalidixic acid in Shigella subgroups in a comparative study between 2001-2003 and 2004-2006[J].Singapore Med J,2009,50(8):791.
9Kansakar P,Malla S,Ghimire GR.Shigella isolates of Nepal:changes in the incidence of shigella subgroups and trends of antimicrobial susceptibility pattern[J].Kathmandu Univ Med J,2007,5(1):32.
10Khatun F,Faruque AS,Koeck JL,et al.Changing species distribution and antimicrobial susceptibility pattern of Shigella over a Shigella over a 29-year period 1980-2008[J].Epidemiol Infect,2010,18:1.
